Gordon Ralph Corey, MD

Professor of Medicine
Gary Hock Professor in Global Health, in the School of Medicine
Vice-Chair for Education and Global Health in the Department of Medicine
Research Professor of Global Health
Professor of Pathology
Member in the Duke Clinical Research Institute
Campus mail 310 Trent Drive Room 235 Trent, Box 90519, Durham, NC 27708
Phone (919) 668-7174
Email address corey001@mc.duke.edu

My research is based at the Duke Clinical Research Institute, a large academic clinical research organization designed to conduct clinical trials from small local studies to worldwide trials. The focus of my research is bacterial infections: complicated skin and skin structure infections; postoperative wound infections; hospital-acquired and ventilator-associated pneumonia; bacteremia; and endocarditis. Many of these trials are conducted in concert with the pharmaceutical industry in order to register new antibiotics. In addition, as director of infectious diseases at the DCRI I oversee the work of the mycology group, and tuberculosis trials. This work also includes work supported by NIH grants including sepsis trials, the Staph Aureus and Staph Epi Bacteremia Groups, and the International Collaboration of Endocarditis. The team of investigators with whom I work is highly experienced, amazingly productive and wonderfully collegial.

As a result of my longstanding interest in tropical medicine and the generosity of my patients as well as the Hubert Family we have been able to establish the Hubert-Yeargan Center for Global Health. As a result we have developed a medical center-wide fellowship in Global Health. I am presently the Director of the Center and the Gary Hock Distinguished Professor of Global Health.

Education and Training

  • Fellowship, Infectious Diseases, Duke University School of Medicine, 1978 - 1980
  • Chief Resident, General Internal Medicine, Duke University School of Medicine, 1977 - 1978
  • Residency, General Internal Medicine, Duke University School of Medicine, 1975 - 1977
  • Internship, General Internal Medicine, Duke University School of Medicine, 1974 - 1975
  • M.D., Baylor University, 1973

Publications

Torres, A., E. Rubinstein, G. R. Corey, M. E. Stryjewski, and S. L. Barriere. “Analysis of Phase 3 telavancin nosocomial pneumonia data excluding patients with severe renal impairment and acute renal failure..” J Antimicrob Chemother 69, no. 4 (April 2014): 1119–26. https://doi.org/10.1093/jac/dkt490.

PMID
24398339
Full Text

Stryjewski, Martin E., and G Ralph Corey. “Methicillin-resistant Staphylococcus aureus: an evolving pathogen..” Clin Infect Dis 58 Suppl 1 (January 2014): S10–19. https://doi.org/10.1093/cid/cit613.

PMID
24343827
Full Text

Corey, G Ralph, Marin H. Kollef, Andrew F. Shorr, Ethan Rubinstein, Martin E. Stryjewski, Alan Hopkins, and Steven L. Barriere. “Telavancin for hospital-acquired pneumonia: clinical response and 28-day survival..” Antimicrob Agents Chemother 58, no. 4 (2014): 2030–37. https://doi.org/10.1128/AAC.02330-13.

PMID
24419353
Full Text

Stryjewski, M. E., A. Lentnek, W. O’Riordan, J. Pullman, P. A. Tambyah, J. M. Miró, V. G. F. Jr, S. L. Barriere, M. M. Kitt, and G. R. Corey. “A randomized Phase 2 trial of telavancin versus standard therapy in patients with uncomplicated Staphylococcus aureus bacteremia: The ASSURE study.” Bmc Infectious Diseases 14, no. 1 (2014). https://doi.org/10.1186/1471-2334-14-289.

Full Text

Tsalik, Ephraim L., Raymond J. Langley, Darrell L. Dinwiddie, Neil A. Miller, Byunggil Yoo, Jennifer C. van Velkinburgh, Laurie D. Smith, et al. “An integrated transcriptome and expressed variant analysis of sepsis survival and death..” Genome Med 6, no. 11 (2014). https://doi.org/10.1186/s13073-014-0111-5.

PMID
25538794
Full Text

Carugati, Manuela, Arnold S. Bayer, Josè M. Miró, Lawrence P. Park, Armenio C. Guimarães, Athanasios Skoutelis, Claudio Q. Fortes, et al. “High-dose daptomycin therapy for left-sided infective endocarditis: a prospective study from the international collaboration on endocarditis..” Antimicrob Agents Chemother 57, no. 12 (December 2013): 6213–22. https://doi.org/10.1128/AAC.01563-13.

PMID
24080644
Full Text

Chirouze, C., E. Athan, F. Alla, V. H. Chu, G. Ralph Corey, C. Selton-Suty, M. -. L. Erpelding, et al. “Enterococcal endocarditis in the beginning of the 21st century: analysis from the International Collaboration on Endocarditis-Prospective Cohort Study..” Clin Microbiol Infect 19, no. 12 (December 2013): 1140–47. https://doi.org/10.1111/1469-0691.12166.

PMID
23517406
Full Text

Stryjewski, Martin E., Steven L. Barriere, Ethan Rubinstein, Fredric C. Genter, Arnold L. Lentnek, Martin Magana-Aquino, Carlos M. Luna, Michael S. Niederman, Antoni Torres, and G Ralph Corey. “Telavancin versus vancomycin for bacteraemic hospital-acquired pneumonia..” Int J Antimicrob Agents 42, no. 4 (October 2013): 367–69. https://doi.org/10.1016/j.ijantimicag.2013.06.003.

PMID
23891527
Full Text

Lalani, Tahaniyat, Vivian H. Chu, Lawrence P. Park, Enrico Cecchi, G Ralph Corey, Emanuele Durante-Mangoni, Vance G. Fowler, et al. “In-hospital and 1-year mortality in patients undergoing early surgery for prosthetic valve endocarditis..” Jama Intern Med 173, no. 16 (September 9, 2013): 1495–1504. https://doi.org/10.1001/jamainternmed.2013.8203.

PMID
23857547
Full Text

Pages